Skip Navigation

Adalvo announces successful DCP submission of Drospirenone + Ethinylestradiol

15 May 2023

Adalvo is pleased to announce the successful DCP Submission for Drospirenone + Ethinylestradiol.

Drospirenone + Ethinylestradiol has been developed, in collaboration with one of our strategic partners, based on the reference brand Yasmin. The product is a low dose oral contraceptive.

According to IQVIA, the INN generated approximately $817mio in global sales in 2022.

Adalvo has entered into a strategic collaboration with a leading partner specializing in women's health, aiming to enhance our offerings in the hormonal products domain. This collaboration expands our portfolio to include a diverse range of oral contraceptives and hormonal replacement products. We are equipped to provide our partners with a comprehensive selection of these products on a global scale.

Our women's health products include:

  • Dienogest, 2 mg
  • Levonorgestrel, 1,5 mg
  • Levonorgestrel+ Ethinylestradiol, 0.10mg+0.02mg
  • Levonorgestrel+ Ethinylestradiol, 0.15mg+0.03mg
  • Drospirenone + Ethinylestradiol, 3mg+0.03mg
  • Drospirenone + Ethinylestradiol, 3mg+0.02mg
  • Desogestrel + Ethinylestradiol, 0.10 mg + 0.02 mg
  • Desogestrel + Ethinylestradiol, 0.15mg+0.03mg
  • Norethisterone + Estradiol, 0.5mg+1mg
  • Norethisterone, 5 mg
  • Desogestrel, 75 mcg
  • Cyproterone + Ethinylestradiol, 2 mg + 0.035 mg
  • Dydrogesterone, 10mg

Partner up now! 
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. – Central & Eastern Europe, Russia & CIS North Europe, APAC, MENA & Israel – Brazil - LATAM (exc. Brazil) & South Europe – Europe – UK/Ireland, North America & South Africa - Head of Global BD&L

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.